THURSDAY 14th of November

  • 12h30-13h45 : REGISTRATION
  • 13h45-14h00 : OPENING CEREMONY
  • 14h00-16h00 : SESSION 1 – RADIOIMAGING IN PRECLINICAL TRIAL AND PHASE III CLINICAL TRIAL
    • A 89Zr complex in pre-clinical phase against cancer (Gilles Gasser).
    • A 99mTc complex in phase III clinical trial against prostate cancer (Roger Alberto).
  • 16h-16h30 : COFFE BREAK
  • 16h30-17h30 : SESSION 2 – ANTIMALARIAL AGENT IN PHASE II CLINICAL TRIAL
    • Ferroquine, phase II, antimalarial drug candidate from Sanofi (Christophe Biot).
  • 17h30-18h00 : SESSION 3 – BIOANALYTICAL CHEMISTRY
    • Bioanalytical chemistry in metal-based drug research (Agilent).
  • 18h00-20h30 : POSTER SESSION

FRIDAY 15th of November

  • 9h00-11h00 : SESSION 4 – METAL COMPLEXES AGAINST CANCER IN PRECLINICAL TRIAL AND PHASE II CLINICAL TRIAL
    • A ferrocenyl compounds in preclinical phase against cancer (Gérard Jaouen).
    • A ruthenium complex beginning clinical phase II trials and Gallium complex against bone malignancies and bone disorders also beginning phase II clinical trials (Bernhard Keppler).
  • 11h-11h30 : COFFEE BREAK
  • 11h30-12h30 : SESSION 5 – METAL COMPLEXES AGAINST CANCER IN PHASE I CLINICAL TRIAL
    • A ruthenium complex as a Photodynamic Therapy (PDT) agent in phase I clinical trial against cancer (Sherri McFarland).
  • 12h30-14h00 : LUNCH
  • 14h00-15h00 : SESSION 6 – METAL COMPLEXES AGAINST CANCER IN PRECLINICAL TRIAL
    • A ruthenium complex in preclinical phase against cancer (Paul Dyson).
  • 15h00-16h30 : SESSION 7 – DEBATE ON THE FUTURE OF METAL-BASED DRUG CANDIDATES
    • What to do to raise the interest of industry with metal-based drug candidates? (Sherri McFarland, Christophe Biot, Roger Alberto, Paul Dyson, Gérard Jaouen, Bernhard Keppler, Gilles Gasser)
  • 16h30 : CLOSING CEREMONY AND POSTER PRIZE AWARDS